Epizyme Inc to Discuss Interim Efficacy and Safety Data from Ongoing Phase 2 Study in Follicular Lymphoma and DLBCL - Call
Llamada en conferencia Epizyme Inc
Epizyme Inc Conference call or earnings call will be held on 14-jun-2017 via an 800 number (toll-free). During the earnings conference call's session Epizyme Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Epizyme Inc for this information
Schedule a teleconference with QCONF and get 5 free calls with our conference service.
Epizyme is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize novel epigenetic therapies for cancer patients. We are leaders in discovering and developing small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs. We are also expanding our development efforts beyond HMTs and are developing small molecule inhibitors of other chromatin modifying proteins, or CMPs. CMPs mediate selective and reversible modifications to chromatin, a complex of chromosomal DNA and histone proteins that controls gene expression. This chromatin remodeling and its resultant control of gene expression are part of a larger regulatory system, commonly referred to as epigenetics. Genetic alterations within CMPs or that indirectly affect CMPs can result in changes to their activity and drive multiple types of cancer, including hematological cancers and solid tumors.Leer más Llamada en conferencia